title: Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia.
abstract: A better understanding of events triggering chronic myeloid leukemia progression is critical for optimized clinical management of chronic myeloid leukemia (CML). We sought to validate that increased expression of Musashi 2 (MSI2), a post-transcription regulator, is associated with progression and prognosis. Screening of 152 patients with CML showed that MSI2 was significantly decreased among patients with CML in chronic phase (CP) at diagnosis (p < 0.0001), but found no significant difference between the normal control group and treated patients with CML in CP. Moreover MSI2 was significantly increased (p < 0.0001) in patients with advance disease (AD) CML. Furthermore, our human hematopoietic cell line data imply that MSI2 and BCR-ABL1 mRNA expression are correlated. However, these data cast a doubt on earlier reports that MSI2 effects HES1 expression via NUMB-NOTCH signaling.
authors.affiliation: Charité, Universitätsmedizin Berlin, Campus Virchow Klinikum, Medizinische Klinik m.S. Hämatologie und Onkologie , Berlin , Germany.
authors.forename: Jaspal
authors.initials: J
authors.lastname: Kaeda
authors.forename: Frauke
authors.initials: F
authors.lastname: Ringel
authors.forename: Christian
authors.initials: C
authors.lastname: Oberender
authors.forename: Ken
authors.initials: K
authors.lastname: Mills
authors.forename: Concetta
authors.initials: C
authors.lastname: Quintarelli
authors.forename: Fabrizio
authors.initials: F
authors.lastname: Pane
authors.forename: Steffen
authors.initials: S
authors.lastname: Koschmieder
authors.forename: Robert
authors.initials: R
authors.lastname: Slany
authors.forename: Rolf
authors.initials: R
authors.lastname: Schwarzer
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Saglio
authors.forename: Philipp
authors.initials: P
authors.lastname: Hemmati
authors.forename: Antje
authors.initials: A
authors.lastname: van Lessen
authors.forename: Leila
authors.initials: L
authors.lastname: Amini
authors.forename: Martin
authors.initials: M
authors.lastname: Gresse
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Vagge
authors.forename: Thomas
authors.initials: T
authors.lastname: Burmeister
authors.forename: Anna
authors.initials: A
authors.lastname: Serra
authors.forename: Anne
authors.initials: A
authors.lastname: Carson
authors.forename: Michaela
authors.initials: M
authors.lastname: Schwarz
authors.forename: Jörg
authors.initials: J
authors.lastname: Westermann
authors.forename: Franziska
authors.initials: F
authors.lastname: Jundt
authors.forename: Bernd
authors.initials: B
authors.lastname: Dörken
authors.forename: Philipp
authors.initials: P
authors.lastname: le Coutre
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D015973:Gene Expression Regulation, Leukemic; D006412:Hematopoietic Stem Cells / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007124:Immunoenzyme Techniques; D015466:Leukemia, Myeloid, Chronic-Phase / Q000235:genetics / Q000378:metabolism* / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics; D016601:RNA-Binding Proteins / Q000235:genetics / Q000378:metabolism*; D060888:Real-Time Polymerase Chain Reaction; D012189:Retrospective Studies; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015398:Signal Transduction; D015996:Survival Rate; D015854:Up-Regulation; D055815:Young Adult
chemical_list: C581634:BCR-ABL1 fusion protein, human; C438151:MSI2 protein, human; D012333:RNA, Messenger; D016601:RNA-Binding Proteins; D016044:Fusion Proteins, bcr-abl
keywords: MSI2; Prognosis; leukemia; stem cell; transformation